Investigating liver damage caused by anti-HIV and anti-COVID-19 drugs and substance use.
Hepatotoxic mechanisms of anti-HIV- and anti-COVID-19 drugs and substance use disorders
This study is looking at how certain antiviral medications for HIV and COVID-19 might harm the liver, especially in people who also struggle with substance use, like alcohol, to help find safer treatment options for those affected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project ID | NIH-11001982 on NIH RePORTER |
What this research studies
This research explores how antiviral medications used for HIV and COVID-19 can lead to liver damage, particularly when combined with substance use disorders. It focuses on understanding the mechanisms behind liver injuries caused by these drugs, especially in patients who may also consume alcohol. By studying the effects of these medications on liver cells, the research aims to identify potential risks and improve treatment strategies for affected individuals. The findings could help in developing safer treatment protocols for patients dealing with both viral infections and substance use issues.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with HIV or COVID-19 who also have a history of substance use, particularly alcohol.
Not a fit: Patients who do not have HIV or COVID-19 and do not engage in substance use may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer antiviral treatments that minimize liver damage for patients with HIV or COVID-19 who also struggle with substance use disorders.
How similar studies have performed: Previous research has indicated that antiviral drugs can cause liver complications, suggesting that this investigation builds on established findings rather than exploring entirely novel territory.
Where this research is happening
Los Angeles, UNITED STATES
- University of Southern California — Los Angeles, United States (Active)
Researchers
- Principal investigator: Ji, Cheng — University of Southern California
- Study coordinator: Ji, Cheng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.